Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers

Siddika E Karakas, Rogelio U. Almario, Kyoungmi Kim

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Fatty acid binding protein (FABP) 4 chaperones free fatty acids (FFAs) in the adipocytes during lipolysis. Serum FFA relates to metabolic syndrome, and serum FABP4 is emerging as a novel risk marker. In 36 overweight/obese women, serum FABP4 and FFA were measured hourly during 5-hour oral glucose tolerance test. Insulin resistance was determined using frequently sampled intravenous glucose tolerance test. Serum lipids and inflammation markers were measured at fasting. During oral glucose tolerance test, serum FABP4 decreased by 40%, reaching its nadir at 3 hours (from 45.3 ± 3.1 to 31.9 ± 1.6 ng/mL), and stayed below the baseline at 5 hours (35.9 ± 2.2 ng/mL) (P < .0001 for both, compared with the baseline). Serum FFA decreased by 10-fold, reaching a nadir at 2 hours (from 0.611 ± 0.033 to 0.067 ± 0.004 mmol/L), then rebounded to 0.816 ± 0.035 mmol/L at 5 hours (P < .001 for both, compared with baseline). Both fasting FABP4 and nadir FABP4 correlated with obesity. Nadir FABP4 correlated also with insulin resistance parameters from frequently sampled intravenous glucose tolerance test and with inflammation. Nadir FFA, but not fasting FFA, correlated with the metabolic syndrome parameters. In conclusion, fasting FABP4 related to metabolic risk markers more strongly than fasting FFA. Nadir FABP4 and nadir FFA measured after glucose loading may provide better risk assessment than the fasting values.

Original languageEnglish (US)
Pages (from-to)1002-1007
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume58
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Fatty Acid-Binding Proteins
Nonesterified Fatty Acids
Blood Proteins
Fasting
Glucose Tolerance Test
Serum
Insulin Resistance
Inflammation
Lipolysis
Adipocytes
Obesity
Lipids
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. / Karakas, Siddika E; Almario, Rogelio U.; Kim, Kyoungmi.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 7, 07.2009, p. 1002-1007.

Research output: Contribution to journalArticle

@article{d6be18310fad4d80b8fae8e39554f7cf,
title = "Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers",
abstract = "Fatty acid binding protein (FABP) 4 chaperones free fatty acids (FFAs) in the adipocytes during lipolysis. Serum FFA relates to metabolic syndrome, and serum FABP4 is emerging as a novel risk marker. In 36 overweight/obese women, serum FABP4 and FFA were measured hourly during 5-hour oral glucose tolerance test. Insulin resistance was determined using frequently sampled intravenous glucose tolerance test. Serum lipids and inflammation markers were measured at fasting. During oral glucose tolerance test, serum FABP4 decreased by 40{\%}, reaching its nadir at 3 hours (from 45.3 ± 3.1 to 31.9 ± 1.6 ng/mL), and stayed below the baseline at 5 hours (35.9 ± 2.2 ng/mL) (P < .0001 for both, compared with the baseline). Serum FFA decreased by 10-fold, reaching a nadir at 2 hours (from 0.611 ± 0.033 to 0.067 ± 0.004 mmol/L), then rebounded to 0.816 ± 0.035 mmol/L at 5 hours (P < .001 for both, compared with baseline). Both fasting FABP4 and nadir FABP4 correlated with obesity. Nadir FABP4 correlated also with insulin resistance parameters from frequently sampled intravenous glucose tolerance test and with inflammation. Nadir FFA, but not fasting FFA, correlated with the metabolic syndrome parameters. In conclusion, fasting FABP4 related to metabolic risk markers more strongly than fasting FFA. Nadir FABP4 and nadir FFA measured after glucose loading may provide better risk assessment than the fasting values.",
author = "Karakas, {Siddika E} and Almario, {Rogelio U.} and Kyoungmi Kim",
year = "2009",
month = "7",
doi = "10.1016/j.metabol.2009.02.024",
language = "English (US)",
volume = "58",
pages = "1002--1007",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers

AU - Karakas, Siddika E

AU - Almario, Rogelio U.

AU - Kim, Kyoungmi

PY - 2009/7

Y1 - 2009/7

N2 - Fatty acid binding protein (FABP) 4 chaperones free fatty acids (FFAs) in the adipocytes during lipolysis. Serum FFA relates to metabolic syndrome, and serum FABP4 is emerging as a novel risk marker. In 36 overweight/obese women, serum FABP4 and FFA were measured hourly during 5-hour oral glucose tolerance test. Insulin resistance was determined using frequently sampled intravenous glucose tolerance test. Serum lipids and inflammation markers were measured at fasting. During oral glucose tolerance test, serum FABP4 decreased by 40%, reaching its nadir at 3 hours (from 45.3 ± 3.1 to 31.9 ± 1.6 ng/mL), and stayed below the baseline at 5 hours (35.9 ± 2.2 ng/mL) (P < .0001 for both, compared with the baseline). Serum FFA decreased by 10-fold, reaching a nadir at 2 hours (from 0.611 ± 0.033 to 0.067 ± 0.004 mmol/L), then rebounded to 0.816 ± 0.035 mmol/L at 5 hours (P < .001 for both, compared with baseline). Both fasting FABP4 and nadir FABP4 correlated with obesity. Nadir FABP4 correlated also with insulin resistance parameters from frequently sampled intravenous glucose tolerance test and with inflammation. Nadir FFA, but not fasting FFA, correlated with the metabolic syndrome parameters. In conclusion, fasting FABP4 related to metabolic risk markers more strongly than fasting FFA. Nadir FABP4 and nadir FFA measured after glucose loading may provide better risk assessment than the fasting values.

AB - Fatty acid binding protein (FABP) 4 chaperones free fatty acids (FFAs) in the adipocytes during lipolysis. Serum FFA relates to metabolic syndrome, and serum FABP4 is emerging as a novel risk marker. In 36 overweight/obese women, serum FABP4 and FFA were measured hourly during 5-hour oral glucose tolerance test. Insulin resistance was determined using frequently sampled intravenous glucose tolerance test. Serum lipids and inflammation markers were measured at fasting. During oral glucose tolerance test, serum FABP4 decreased by 40%, reaching its nadir at 3 hours (from 45.3 ± 3.1 to 31.9 ± 1.6 ng/mL), and stayed below the baseline at 5 hours (35.9 ± 2.2 ng/mL) (P < .0001 for both, compared with the baseline). Serum FFA decreased by 10-fold, reaching a nadir at 2 hours (from 0.611 ± 0.033 to 0.067 ± 0.004 mmol/L), then rebounded to 0.816 ± 0.035 mmol/L at 5 hours (P < .001 for both, compared with baseline). Both fasting FABP4 and nadir FABP4 correlated with obesity. Nadir FABP4 correlated also with insulin resistance parameters from frequently sampled intravenous glucose tolerance test and with inflammation. Nadir FFA, but not fasting FFA, correlated with the metabolic syndrome parameters. In conclusion, fasting FABP4 related to metabolic risk markers more strongly than fasting FFA. Nadir FABP4 and nadir FFA measured after glucose loading may provide better risk assessment than the fasting values.

UR - http://www.scopus.com/inward/record.url?scp=66349128493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349128493&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2009.02.024

DO - 10.1016/j.metabol.2009.02.024

M3 - Article

C2 - 19394980

AN - SCOPUS:66349128493

VL - 58

SP - 1002

EP - 1007

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 7

ER -